Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 187

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Open access
Fakhouri, Fadi, Fila, Marc, Hummel, Aurélie, Ribes, David, Sellier-Leclerc, Anne-Laure, Ville, Simon, Pouteil-Noble, Claire, Coindre, Jean-Philippe, Le Quintrec, Moglie, Rondeau, Eric, Boyer, Olivia, Provôt, François, Djeddi, Djamal, Hanf, William, Delmas, Yahsou, Louillet, Ferielle, Lahoche, Annie, Favre, Guillaume, Châtelet, Valérie, Launay, Emma Allain, Presne, Claire, Zaloszyc, Ariane, Caillard, Sophie, Bally, Stéphane, Raimbourg, Quentin, Tricot, Leïla, Mousson, Christiane, Le Thuaut, Aurélie, Loirat, Chantal, Frémeaux-Bacchi, Véronique · 2021 · Blood

Abstract

The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter open-label study to assess eculizumab discontinuation in children and adults with aHUS. Fifty-five patients (including 19 children) discontinued eculizumab (mean treatment duration, 16.5 months). Twenty-eight patients (51%) had rare variants in complement genes, mostly in MCP (n = 12; 22%), CFH (n = 6; 11%), and CFI (n = 6; 10%). At eculizumab discontinuation, 17 (30%) and 4 patients (7%) had stage 3 and 4 chronic kidney disease, respectively. During follow-up, 13 patients (23%; 6 children and 7 adults) experienced aHUS relapse. In multivariable analysis, female sex and presence of a rare variant in a complement gene were associated with an increased risk of aHUS relapse, whereas requirement for dialysis during a previous episode of acute aHUS was not. In addition, increased sC5b-9 plasma level at eculizumab discontinuation was associated with a higher risk of aHUS relapse in all patients and in the subset of carriers with a complement gene rare variant, both by log-rank test and in multivariable analysis. Of the 13 relapsing patients, all of whom restarted eculizumab, 11 regained their baseline renal function and 2 had a worsening of their preexisting chronic kidney disease, including 1 patient who progressed to end-stage renal disease. A strategy of eculizumab discontinuation in aHUS patients based on complement genetics is reasonable and safe. It improves the management and quality of life of a sizeable proportion of aHUS patients while reducing the cost of treatment. This trial was registered at www.clinicaltrials.gov as #NCT02574403.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020009280

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Metadata

Authors
Fakhouri, F., Fila, M., Hummel, A., Ribes, D., Sellier-Leclerc, A.-L., Ville, S., Pouteil-Noble, C., Coindre, J.-P., Le Quintrec, M., Rondeau, E., Boyer, O., Provôt, F., Djeddi, D., Hanf, W., Delmas, Y., Louillet, F., Lahoche, A., Favre, G., Châtelet, V., Launay, E. A., Presne, C., Zaloszyc, A., Caillard, S., Bally, S., Raimbourg, Q., Tricot, L., Mousson, C., Le Thuaut, A., Loirat, C., & Frémeaux-Bacchi, V.
Venue
Blood
Published
2021-05-06
Volume
137
Issue
18
Pages
2438-2449
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3108107578
Cited by
187
References
1
FWCI
6.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. https://app.cochat.ai/papers/10.1182/blood.2020009280
The paper
Fakhouri, F., Fila, M., Hummel, A., Ribes, D., Sellier-Leclerc, A.-L., Ville, S., Pouteil-Noble, C., Coindre, J.-P., Le Quintrec, M., Rondeau, E., Boyer, O., Provôt, F., Djeddi, D., Hanf, W., Delmas, Y., Louillet, F., Lahoche, A., Favre, G., Châtelet, V., . . . Frémeaux-Bacchi, V. (2021). Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. https://doi.org/10.1182/blood.2020009280

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.